NRx Pharmaceuticals announced that it intends to offer to sell shares of its common stock in an underwritten public offering of a limited number of shares. All of the shares of common stock are to be sold by the company. NRx Pharmaceuticals intends to use the net proceeds from the offering for working capital and general corporate purposes. The company may also use the net proceeds from the offering to repay certain outstanding debt. EF Hutton is acting as the sole book-running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRXP:
- NRX Pharmaceuticals Amends Repayment Terms with Streeterville Capital
- NRx Pharmaceuticals Secures Funding and Expands Alvogen Partnership
- NRx Pharmaceuticals receives $5M milestone payment
- NRx reports comments from its partner Lotus on its recent financial filing
- NRx Pharmaceuticals announces incorporation of Hope Therapeutics